A common flu virus could be used to overcome patients’ resistance to certain cancer drugs — and improve how those drugs kill cancer cells, according to new research from Queen Mary University of London (QMUL).
The work, funded by UK charity Pancreatic Cancer Research Fund, contributes to a growing area in cancer treatment in which viruses are harnessed to kill cancer cells.
Viruses can be modified to specifically infect cancer cells, and use them as a factory to generate thousands of new viruses, replicating until the cancer cell bursts. The virus copies will then spread and infect surrounding tumour cells and repeat the process, leaving healthy cells unharmed.
But the body’s immune system will usually kill off the virus before it is able to infect all the cells within a tumour. In pancreatic cancer, therefore, drugs such as gemcitabine are currently the most common treatment — they work by damaging the DNA in the cancer cells, so they are unable to divide successfully. This damage triggers a process called apoptosis, in which damaged or unhealthy cells are forced to self-destruct.
Over time, however, the cancer cell becomes able to delay apoptosis in order to repair the damage to its DNA, which means that the cells survive and continue to divide and spread and the drug becomes less effective.
In a study published in the journal Oncotarget, the team at QMUL’s Barts Cancer Institute introduced a genetic modification to the virus, called adenovirus, to give it an extra weapon against cancer cells.
By switching off a particular gene in the virus which counteracts apoptosis, the scientists found cancer cells studied in the laboratory were unable to delay apoptosis and so forced to die without dividing. The modified virus still infects some cancer cells and replicates until the cell bursts, but by also preventing the cancer cells from developing drug resistance, it works with the anti-cancer drug to increase the number of cells that are killed.
“Many cancers — including pancreatic cancer — become resistant to treatments like gemcitabine, and currently there’s no way to get round that,” explains Dr Gunnel Halldèn, who led the research. “The virus that we have modified re-sensitises the resistant cancer cell by preventing the cell from repairing itself. The virus alone will kill some tumour cells, but in combination with the drug, the number of cells that are killed is greatly increased.
“Because the virus improves the efficacy of the drug, it means it could also be possible to give lower doses, which will also reduce the unpleasant side-effects associated with chemotherapy,” she adds.
Developing virus-based cancer therapies has been a key goal in cancer research for several years and some technologies have already moved into the clinic: last year, for example, a melanoma therapy, based on a herpes virus called T-VEC, was approved for use in the US and in Europe.
The QMUL research is at an early stage, but the team believe they have found a promising new route for developing combination treatments for pancreatic cancer.
The next step for the researchers will be to test other modified versions of adenovirus to better understand the exact mechanism through which it enhances cell killing. Further modifications will also be made to enable the virus to trigger the body’s immune system, which will attack any cancer cells that have not been infected by the virus.
The Latest on: Virus-based cancer therapies
via Google News
The Latest on: Virus-based cancer therapies
- Vyriad Inc. Announces Development of a New Antibody Test to Determine Protective Immunity From COVID-19on May 12, 2020 at 6:00 am
Vyriad test detects SARS-CoV-2 virus-neutralizing antibodies Developed as part of an ongoing collaboration with Regeneron ROCHESTER, Minn., May 12, 2020 (GLOBE NEWSWIRE) ...
- Themis collaborates with ABL Europe to manufacture its SARS-CoV-2 Vaccine Candidate in Franceon May 11, 2020 at 6:12 am
Themis, a clinical-stage biopharmaceutical company focused on immunomodulation therapies for infectious diseases and cancer, and ABL Europe (ABL), a global Contract Development and Manufacturing Organ ...
- Transgene Reports Q1 2020 Financial Position and Business Updateon May 6, 2020 at 9:16 am
Regulatory News: Transgene (Euronext Paris: TNG) (Paris:TNG), a biotech company that designs and develops virus-based immunotherapies for ...
- Transgene Reports Q1 2020 Financial Position and Business Updateon May 6, 2020 at 8:52 am
TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today announces its business update for the quarter ending March 31, 2020, and provides ...
- Oncolytic Newcastle Disease Virus for Cancer Therapyon May 2, 2020 at 5:00 pm
Summary of clinical trials with Newcastle disease virus-based cellular vaccines and oncolysates. Vaccine preparation Type of cancer Type ... in development of treatment strategies with greatest ...
- Ottawa researchers eye cancer fighting viruses in search for COVID-19 vaccineon April 28, 2020 at 3:57 pm
Researchers at the Ottawa Hospital have received a $250,000 grant for research on cancer-fighting viruses to create a vaccine for COVID-19.
- Big Pharma Gaining Increased Interest in Fighting Cancer With Oncolytic Virus Therapieson April 24, 2020 at 1:26 am
Before it's here, it's on the Bloomberg Terminal.
- can hickeys cause canceron April 3, 2019 at 6:17 pm
s not impossible that a hickey could cause a blood clot that leads ... kill more people than breast cancer, car crashes, and AIDS combined ... Can we please stop having this debate? But three out ...
- World first as viral immunotherapy for skin cancer shows patient benefit in Phase III trialon May 26, 2015 at 3:43 pm
World-first viral therapy ... cancer cells and bursts them from within. It has been genetically engineered to produce a molecule called GM-CSF, which stimulates the immune system to attack and destroy ...
- Immunotherapy in Nonmelanoma Skin Canceron June 29, 2012 at 3:13 am
peptide vaccines and dendritic cell-based strategies have been proved to be effective in the treatment of nonmelanoma skin cancer. COX inhibitors, as well as plant saccharides, have been shown to ...
via Bing News